Logo image of VVY.AS

VIVORYON THERAPEUTICS NV (VVY.AS) Stock Fundamental Analysis

Europe - Euronext Amsterdam - AMS:VVY - NL00150002Q7 - Common Stock

1.606 EUR
0 (-0.25%)
Last: 12/8/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, VVY scores 2 out of 10 in our fundamental rating. VVY was compared to 83 industry peers in the Biotechnology industry. VVY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VVY does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VVY has reported negative net income.
In the past year VVY has reported a negative cash flow from operations.
In the past 5 years VVY always reported negative net income.
In the past 5 years VVY always reported negative operating cash flow.
VVY.AS Yearly Net Income VS EBIT VS OCF VS FCFVVY.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -194.45%, VVY is not doing good in the industry: 91.57% of the companies in the same industry are doing better.
The Return On Equity of VVY (-392.39%) is worse than 67.47% of its industry peers.
Industry RankSector Rank
ROA -194.45%
ROE -392.39%
ROIC N/A
ROA(3y)-121.31%
ROA(5y)-94.21%
ROE(3y)-158.36%
ROE(5y)-122.89%
ROIC(3y)N/A
ROIC(5y)N/A
VVY.AS Yearly ROA, ROE, ROICVVY.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VVY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VVY.AS Yearly Profit, Operating, Gross MarginsVVY.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600

More info and screens

4

2. Health

2.1 Basic Checks

VVY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VVY remains at a similar level compared to 1 year ago.
VVY has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, VVY has a worse debt to assets ratio.
VVY.AS Yearly Shares OutstandingVVY.AS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
VVY.AS Yearly Total Debt VS Total AssetsVVY.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

VVY has an Altman-Z score of -35.08. This is a bad value and indicates that VVY is not financially healthy and even has some risk of bankruptcy.
VVY's Altman-Z score of -35.08 is on the low side compared to the rest of the industry. VVY is outperformed by 84.34% of its industry peers.
VVY has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.00, VVY belongs to the best of the industry, outperforming 86.75% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -35.08
ROIC/WACCN/A
WACC7.25%
VVY.AS Yearly LT Debt VS Equity VS FCFVVY.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

VVY has a Current Ratio of 4.04. This indicates that VVY is financially healthy and has no problem in meeting its short term obligations.
VVY has a better Current ratio (4.04) than 75.90% of its industry peers.
A Quick Ratio of 4.04 indicates that VVY has no problem at all paying its short term obligations.
VVY has a better Quick ratio (4.04) than 78.31% of its industry peers.
Industry RankSector Rank
Current Ratio 4.04
Quick Ratio 4.04
VVY.AS Yearly Current Assets VS Current LiabilitesVVY.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.00% over the past year.
The Revenue has grown by 100.00% in the past year. This is a very strong growth!
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.62%
Revenue 1Y (TTM)100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 121.74% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y46.3%
EPS Next 2Y13.32%
EPS Next 3Y7.04%
EPS Next 5Y121.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VVY.AS Yearly Revenue VS EstimatesVVY.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2021 2023 2029 2030 0 500M 1B 1.5B
VVY.AS Yearly EPS VS EstimatesVVY.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 20 30 40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VVY. In the last year negative earnings were reported.
Also next year VVY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VVY.AS Price Earnings VS Forward Price EarningsVVY.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VVY.AS Per share dataVVY.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.32%
EPS Next 3Y7.04%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VVY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIVORYON THERAPEUTICS NV

AMS:VVY (12/8/2025, 7:00:00 PM)

1.606

0 (-0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-04 2025-12-04
Earnings (Next)04-27 2026-04-27/amc
Inst Owners10.37%
Inst Owner ChangeN/A
Ins Owners9.32%
Ins Owner ChangeN/A
Market Cap47.55M
Revenue(TTM)N/A
Net Income(TTM)-12.48M
Analysts85.71
Price Target5.23 (225.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)3.45%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 14.95
P/tB 20.24
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS0.11
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -194.45%
ROE -392.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.31%
ROA(5y)-94.21%
ROE(3y)-158.36%
ROE(5y)-122.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.04
Quick Ratio 4.04
Altman-Z -35.08
F-Score2
WACC7.25%
ROIC/WACCN/A
Cap/Depr(3y)105.74%
Cap/Depr(5y)75.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.62%
EPS Next Y46.3%
EPS Next 2Y13.32%
EPS Next 3Y7.04%
EPS Next 5Y121.74%
Revenue 1Y (TTM)100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y60.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.14%
EBIT Next 3Y9.82%
EBIT Next 5YN/A
FCF growth 1Y67.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.43%
OCF growth 3YN/A
OCF growth 5YN/A

VIVORYON THERAPEUTICS NV / VVY.AS FAQ

What is the ChartMill fundamental rating of VIVORYON THERAPEUTICS NV (VVY.AS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VVY.AS.


What is the valuation status for VVY stock?

ChartMill assigns a valuation rating of 0 / 10 to VIVORYON THERAPEUTICS NV (VVY.AS). This can be considered as Overvalued.


Can you provide the profitability details for VIVORYON THERAPEUTICS NV?

VIVORYON THERAPEUTICS NV (VVY.AS) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for VVY stock?

The Earnings per Share (EPS) of VIVORYON THERAPEUTICS NV (VVY.AS) is expected to grow by 46.3% in the next year.